Tomohiro Ozaki

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer

Isamu Okamoto, Hiroshi Nokihara, Shogo Nomura et al. · JAMA Oncology · 2020 · 67 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba et al. · Journal for ImmunoTherapy of Cancer · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15

Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience

Toshio Shimizu, Taroh Satoh, Kenji Tamura et al. · International Journal of Clinical Oncology · 2007 · 25 citations

Medicine, Oncology, Pharmacotherapy +11

Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer

Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi et al. · European Journal of Cancer · 2021 · 22 citations

Medicine, Oncology, Pharmacology +12